KTN3379 (Table 3) is an anti-HER3 monoclonal antibody that binds to an epitope that locks HER3 in its inactive conformation and inhibits both ligand-dependent and ligand-independent signaling.[131] Preclinical data show that the anti-tumor effects of KTN3379 were attenuated in PTEN-knockdown tumor cell lines.[132] A phase I study (NCT02014909) has proven safety of KTN3379 alone or in combination with cetuximab, erlotinib, vemurafenib or trastuzumab in patients with advanced solid tumors.[133]. Here, ERBB3 is linked to neoplasm.